Program for website

PROGRAM AGENDA Program Agenda Saturday, June 25, 2022 Time (UTC) Item Room 08:30 – 16:30 116 08:30 – 10:00 HTAi Board of Directors Meeting (Invitation Only) 114 Workshops: • Advanced Workshop In Information Retrieval: Addressing Lifecycles Of The Literature In Health Technology Assessment • How To Incorporate Environmental Impact To Quality Of Care And 117 Guidelines • How To Perform A Trial-Based Economic Evaluation Using R 215 • HTA 101: Introduction To Health Technology Assessment 315 10:00 – 10:30 Morning Break 1st Floor Foyer 10:30 – 12:00 12:00 – 13:00 Continuation of the Workshops Various 13:00 – 14:30 Lunch (Workshop attendees only) 1st Floor Foyer 14:30 – 15:00 15:00 – 16:30 Workshops: • Advanced Workshop In Information Retrieval: Addressing Lifecycles Of The 114 Literature In Health Technology Assessment (Cont.) • Integrating Patient And Citizen Perspectives: Resources And Challenges 117 For A Lifecycle Approach • Lifecycle Approach To Regulatory, Management And Assessment Of Health 215 Technologies: Is It The Solution For Resource Constraint Settings? • An Interactive Workshop On The Theory And Practice Of Measuring The 315 Impact Of Health Technology Assessment • Generating And Using Real World Evidence For Health Technology 417 Assessment Afternoon Break 1st Floor Foyer Continuation of the Workshops Various 34

PROGRAM AGENDA Sunday, June 26, 2022 Time (UTC) Item Room 08:30 – 10:00 Workshops: 110 09:00 – 12:00 • Early Awareness And Alert Systems (EAA) On New, Emerging And Obsolete 10:00 – 10:30 Technologies 114 10:30 – 12:00 117 12:00 – 13:00 • HTA 102. Hospital-Based HTA 215 13:00 – 15:30 315 13:00 – 14:30 • Values In Doing Assessments Of Healthcare Technologies (VALIDATE) 417 14:30 – 15:00 • An Introduction To Early Health Technology Assessment 1st Floor Foyer 15:00 – 16:30 Various 16:30 – 17:30 • Research Oriented Market Access for Adopting High-Cost Therapies – 1st Floor Foyer 18:30 – 22:00 Principles and Practice 417 Global Policy Forum Business and Topic Scoping Meeting (Invitation Only) 110 114 Morning Break 117 Continuation of the Workshops 215 Lunch (Workshop attendees only) EuroScan Meeting (Invitation only) 315 Workshops: 1st Floor Foyer • Introduction to Ethics in Health Technology Assessment Various 417 • HTA 102. Hospital-Based HTA (Cont.) Mies Bouwman Foyer, Beatrix • The Use Of Evidence-Informed Deliberative Processes For Health Building Technology Assessment In Low- and Middle-Income Countries • Reducing The Computational Burden Of Health Economic Models And Analyses Using Metamodeling • Exploring Methods for Evaluating Impact of Patient and Public Involvement in the Assessment of Technologies Along their Lifecycle Afternoon Break Continuation of the Workshops HTAi Scientific Development and Capacity Building Committee Meeting Welcome Reception 35

PROGRAM AGENDA Monday, June 27, 2022 Time (UTC) Item Room 08:00 – 09:00 Beatrix Theatre 09:00 - 10:15 Welcome Ceremony 10:15 – 10:45 • Keynote Address, Prof. Marcel Levi, Chairman, Netherlands Organization Beatrix Theatre 10:45 – 12:00 12:10 – 13:10 for Scientific Research (NOW), The Netherlands Expo Hall Mies Bouwman 13:15 – 14:15 Plenary Session 1 - Adopting a Lifecycle Approach in HTA: Consequences for Beatrix Theatre Priority-Setting and International Collaboration 114 Morning Break 117 215 Poster Presentations 315 Beatrix Theatre Exclusive Symposium - You Better Believe It: Methodologies To Address 417 Concerns In Using Real-World Evidence For Measures Of Treatment Virtual Effectiveness (F-Hoffman-La Roche Ltd) Expo Hall Mies Bouwman Oral Presentation Session 1: 215 • OS01 Discrete Choice Experiments (DCE) 315 417 • OS02 Early HTA 114 • OS03 Economic Evaluation 117 • OS04 European Collaboration • OS05 Patient and Clinician Involvement • OS06 Systematic Reviews for HTA • OS07 Quality of Evidence Lunch Poster Presentations HTAi Interest Group Meetings (HTAi Members Only): • Real World Evidence & Artificial Intelligence • Medical Devices • Hospital Based HTA Symposia: • Making Gene and Cell Therapies Reality for Patients: How HTA and Novel Payment Solutions Play a Central Role (F-Hoffman-La Roche Ltd) • What does ‘Value’ mean in Cancer Policy & Practice? Interventions for Improved Patient Outcomes across Geographies (Merck & Co., Inc.) (continued on next page) 36

PROGRAM AGENDA (Monday, June 27, 2022 continued) Time (UTC) Item Room 14:20 – 15:35 Panel Presentation Session 1: 114 15:45 – 16:45 16:45 – 17:15 • PN01 Building Bridges Between Patient And Treatment - Perspectives On 117 Harmonizing Health Technology Assessment With Up And Down-Stream Stakeholders 417 • PN02 Health Technology Assessment in Situations of Uncertainty: The 315 Case of COVID-19 Technologies Virtual • PN03 The Year Of Change: From National To European Health Technology Assessment Procedures Beatrix Theatre • PN04 Horizon Scanning for New and Emerging Technologies. Experiences Virtual Along the World., So Similar, So Different 215 • PN05 Developing HTA in the Balkans – A Roadmap for Success with International Collaboration 114 117 • PN06 A Lifecycle Approach to Promote Engagement and Efficiency in Beatrix Theatre HTA: 2022 HTAi Global Policy Forum Summary 315 417 • PN07 Working Together In Health Technology Assessment On Oncology Virtual Immunotherapy Lifecycle: Opportunities And Challenges In East Asia Virtual 215 • PN11 Can Social Media Research help to improve public confidence in Expo Hall Health Technology Assessment (HTA) and healthcare decision making? Mies Bouwman Oral Presentation Session 2: • OS09 HTA in World • OS10 Artificial Intelligence • OS11 Horizon Scanning • OS12 Lifecycle • OS13 Pricing • OS14 Real World Data – Use • OS15 Diabetes • OS16 Multi-Stakeholder Involvement Afternoon Break Poster Presentations (continued on next page) 37

PROGRAM AGENDA (Monday, June 27, 2022 continued) Time (UTC) Item Room 17:15 – 18:30 Panel Presentation Session 2: 19:00 – 20:00 • PN09 The International Horizon Scanning Initiative: Empowering 114 Governments to Identify and Negotiate Fair Prices for Innovative Health Technologies • PN10 From Thought to Action: Legitimate Decision Making and The Role Virtual of Stakeholders in the HTA Processes • PN11 Can Social Media Research Help to Improve Public Confidence in 215 Health Technology Assessment (HTA) and Healthcare Decision Making? • PN12 Would the Novel Elements of Value Contribute to Equitable Access 315 to New Medical Technologies? – A Multi-stakeholder perspective. • PN13 Deep Dive on Uncertainty – A Multistakeholder Discussion Hosted by 417 the HTAi-DIA Joint Working Group • PN14 Deliberative Processes for Informed Decision – Making by Health Beatrix Theatre Technology Assessment: HTAi Latin America Policy Forum 2021 Findings • PN15 Patient and Public Participation in Health Technology Assessment’s 117 Organizational Domain: Approaches and Opportunities • PN16 Impact of Health Policies on HTA Virtual Annual General Meeting (HTAi Members Only) Beatrix Theatre 38

PROGRAM AGENDA Tuesday, June 28, 2022 Time (UTC) Item Room 08:10 – 09:25 09:25 – 09:35 Plenary Session 2 - Public Confidence in Healthcare Decision-Making Beatrix Theatre 09:50 – 11:05 Special Session - HTA in Challenging Times: Experience in Ukraine Beatrix Theatre 11:05 – 11:35 11:35 – 12:55 Oral Presentation Session 3: • OS17 Children and Paediatrics 114 • OS18 Horizon Scanning 117 • OS19 Guidance for HTA 215 • OS20 Patient Perspectives Beatrix Theatre • OS21 Treatment Value 417 • OS22 HTA Tools Virtual • OS23 COVID Virtual • OS24 Environmental Impact 315 Morning Break Expo Hall Poster Presentations Mies Bouwman Panel Presentation Session 3: • PN17 Fit For Purpose Novel Payment Models to Increase Patient Access to Virtual Cell and Gene Therapies: Let’s Work Together • PN18 Real-world Evidence’s Role in Lifecycle Management: Learnings from 117 ICER and NICE’s Demonstration Projects • PN19 Journal Submissions - Some Useful Tips For Success 215 • PN20 Developing A Multi-Stakeholder Shared Learning Platform To 315 Improve Understanding In The Use And Acceptance Of RWE • PN21 Joint Scientific Consultations: How Will the Present Inform the 417 Future? • PN22 The Added Value Of A Value-Oriented Perspective In Health 114 Technology Assessment • PN23 A Lifecycle Approach in Assessing Digital Applications: in Silos or Beatrix Theatre Teaming up Internationally? • PN24 Applying Patient Preferences in HTA: Do Preferences and Can Virtual Preferences Influence HTA Decision Making? (continued on next page) 39

PROGRAM AGENDA (Tuesday, June 28, 2022 continued) Time (UTC) Item Room 12:55 – 13:55 Lunch Expo Hall Poster Presentations Mies Bouwman 14:00 – 15:00 HTAi Interest Group Meetings (HTAi Members Only) • Ethics 315 15:10 – 16:25 • Patient and Citizen Involvement 215 16:25 – 16:55 • Public Health 417 IJTAHC Editorial Board Meeting (Invitation Only) 110 Symposium • Facilitating RWE Use In HTA: Creating A Taxonomy For Problem Solving 114 And Data Legitimization (Novartis Pharma AG) Beatrix Theatre Oral Presentation Session 4: 117 • OS25 Patient Involvement 215 • OS26 Decision Making 315 • OS27 Virtual 417 • OS28 Real World Data – Impact 114 • OS29 PROMS Virtual • OS30 Stakeholder Engagement Beatrix Theatre • OS32 Priority Setting Exclusive Symposium – Capacity-Enhancing Innovations as Enablers for Expo Hall Resilient Healthcare Systems (Edwards Lifesciences) Mies Bouwman Afternoon Break Poster Presentations (continued on next page) 40

PROGRAM AGENDA (Tuesday, June 28, 2022 continued) Time (UTC) Item Room 16:55 – 18:10 Panel Presentation Session 4: 114 18:15 – 19:15 19:30 – 23:59 • PN25 Enhancing ‘Public Confidence in Healthcare Decision-Making’ in Virtual Low-and Middle-Income Countries through Stakeholder- and Context- 215 Conscious Health Technology Assessment (HTA) 315 417 • PN26 How May the Lifecycle Approach Feed into HTA Capacity Building Strategies in Low- and Middle-Income Countries (LMICs)? Beatrix Theatre Virtual • PN27 Sustainable Modeling: Taking A Lifecycle Approach To Model 117 Development To Increase Assessment Efficiency And Validity 215 • PN28 EU HTA Regulation: Improved Access or Layering of Processes? 315 417 • PN29 Patient Registries Providing Real-World Evidence to Support Railway Museum, a Lifecycle Approach for HTA of Expensive Drugs, from Different Malibaanstation Perspectives. 16, 3581 XW • PN30 HTA in Asia Post-COVID-19: HTAi Asia Policy Forum 2021 Findings • PN31 Regulatory and Health Technology Assessment Alignment: A Match Made in Heaven or Irreconcilable Differences? • PN32 Do Differences In HTA Deliberative Structures Affect Confidence In The Outputs? A Discussion And Proposed Research Agenda HTAi Interest Group Meetings (HTAi Members Only) • HTA in Developing Countries • Information Retrieval • Disinvestment and Early Awareness Conference Dinner (Ticket purchase necessary) 41

PROGRAM AGENDA Wednesday, June 29, 2022 Time (UTC) Item Room 08:45 – 09:15 Beatrix Theatre 09:25 – 10:40 David Banta Tribute and Award Presentation 315 10:40 – 11:10 Panel Presentation Session 5: Beatrix Theatre 11:10 – 12:45 417 12:45 – 14:00 • PN33 Patient Involvement in Health Technology Assessment (HTA) – Are 114 We All on the Same Page? 117 215 • PN34 Creating Political, Societal and Professional Support for Sustainable Healthcare Choices Virtual Virtual • PN35 Qualitative Evidence: A Methodology That Can Guide Lifecycle Health Technology Assessment Expo Hall Beatrix Theatre • PN36 Beyond Checking The Boxes: Guidance Of The Joint HTAi – ISPOR Beatrix Theatre Task Force Deliberative Processes For HTA • PN37 Collaboration to Overcome Challenges in Generation and Interpretation of Evidence for Rare Disease Treatments • PN38 Outcome-Based Reimbursement and Delayed-Payment Schemes for New Technologies Central and Eastern European and Middle-Eastern Countries • PN39 A Lifecycle Approach to HTA: The Role of Implementation Alongside Economic Evaluation • PN40 Value From a Multi-stakeholder Perspective: An Assessment Framework for Digital Health Solutions to Improve Chronic Disease Management Morning Break Plenary Session 3 - Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians Closing Ceremony and Award Presentations 42